The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine

(1) Background: Decitabine and azacitidine are cytosine analogues representing the class of drugs interfering with DNA methylation. Due to their molecular homology and similar clinical application, both drugs are often regarded as interchangeable. Despite their unique mechanism of action the studies...

Full description

Bibliographic Details
Main Authors:	Alicja Pawlak, Kinga Chybicka, Ewa Zioło, Leon Strządała, Wojciech Kałas
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Cancers
Subjects:	azacitidine decitabine colon cancer epigenetic drug cellular senescence chemotherapy
Online Access:	https://www.mdpi.com/2072-6694/14/6/1530

Similar Items

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01)

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
by: Miriam Saiz-Rodríguez, et al.
Published: (2021-11-01)

Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
by: Jorge Labrador, et al.
Published: (2022-05-01)

Demethylating Agents in the Treatment of Cancer
by: Paul M. Howell, Jr., et al.
Published: (2010-07-01)

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
by: Bingbing Wen, et al.
Published: (2020-03-01)

Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
by: Jiale Ma, et al.
Published: (2021-08-01)

Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis
by: Frontiers Production Office
Published: (2023-05-01)

Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2’-deoxycytidine, DAC)
by: Richard L Momparler
Published: (2013-07-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis
by: Jun Li, et al.
Published: (2022-12-01)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
by: Xiaoshuang Kong, et al.
Published: (2023-04-01)

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
by: Anwarul Islam
Published: (2023-08-01)

Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression
by: Janneke F. Linnekamp, et al.
Published: (2021-05-01)

Comparison of the effects of olsalazine and decitabine on the expression of CDH1 and uPA genes and cytotoxicity in MDA-MB-231 breast cancer cells
by: Misagh Mohammadi Asl, et al.
Published: (2021-01-01)

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
by: Harry Ross Powers, et al.
Published: (2014-09-01)

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
by: Smith Kungwankiattichai, et al.
Published: (2022-02-01)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
by: Sonia Abou Najem, et al.
Published: (2019-11-01)

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine
by: Lu Liu, et al.
Published: (2024-02-01)

Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes
by: Moreno Vanegas Y, et al.
Published: (2022-12-01)

Bone Marrow Microenvironment-Induced Chemoprotection in <i>KMT2A</i> Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
by: Kara M. Lehner, et al.
Published: (2023-06-01)

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
by: Nicholas J. Short, et al.
Published: (2022-01-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
by: Lien Provez, et al.
Published: (2023-01-01)

The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer
by: Yan Zhang, et al.
Published: (2017-09-01)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
by: Seungyoun Kim, et al.
Published: (2021-12-01)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
by: Xin Yan, et al.
Published: (2020-10-01)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
by: Jun-Feng Zhu, et al.
Published: (2022-10-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
by: Chiara R. Dart, et al.
Published: (2021-07-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

Hairpin-bisulfite sequencing of cells exposed to decitabine documents the process of DNA demethylation
by: Issam M Mayyas, et al.
Published: (2021-11-01)

High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia
by: Sing-Ting Wang, et al.
Published: (2022-11-01)

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
by: Francesco D’Alò, et al.
Published: (2021-04-01)

Physicochemical stability of azacitidine suspensions at 25 mg/mL in polypropylene syringes stored under different conditions of storage
by: Trambloy Quentin, et al.
Published: (2022-06-01)

Stability of 25 mg/mL Azacitidine Suspensions Kept in Fridge after Freezing
by: Balouzet Clara, et al.
Published: (2017-03-01)

Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
by: Kamel Laribi, et al.
Published: (2019-05-01)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
by: Asude Kara, et al.
Published: (2017-05-01)

Acute appendicitis in acute leukemia and the potential role of decitabine in the critically ill patient
by: Deepti Warad, et al.
Published: (2015-01-01)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
by: Karahoca Metin, et al.
Published: (2013-02-01)

A Novel Cognition of Decitabine: Insights into Immunomodulation and Antiviral Effects
by: Ji Xiao, et al.
Published: (2022-03-01)

Therapeutic effect of folic acid combined with decitabine on diabetic mice
by: Gang Du, et al.
Published: (2023-11-01)